Right versus left ventricular remodeling in heart failure due to chronic volume overload: pressure-volume and proteome analysis

Tereza Havlenova

Second Faculty of Medicine, Charles University, Prague

Petra Skaroupkova

Institute for Clinical and Experimental Medicine - IKEM

Matus Miklovic

Second Faculty of Medicine, Charles University, Prague

Matej Behounek

BIOCEV, Charles University

Martin Chmel

BIOCEV, Charles University

Dagmar Jarkovska

Faculty of Medicine in Pilsen, Charles University

Jitka Svirglerova

Faculty of Medicine in Pilsen, Charles University

Milan Stengl

Faculty of Medicine in Pilsen, Charles University

Michal Kolar

Institute of Molecular Genetics

Jiri Novotny

Institute of Molecular Genetics

Jan Benes

Institute for Clinical and Experimental Medicine - IKEM

Ludek Cervenka

Institute for Clinical and Experimental Medicine - IKEM

Jiri Petrak

BIOCEV, Charles University

Vojtech Melenovsky (✉ vojtech.melenovsky@ikem.cz)

Institute for Clinical and Experimental Medicine - IKEM

Research Article

Keywords: biventricular response, volume overload, heart failure, aorto-caval fistula (ACF)/sham operation

Posted Date: April 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-399870/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Mechanisms of right ventricular (RV) dysfunction in heart failure (HF) are poorly understood. RV response to volume overload (VO), a common contributing factor to HF, is rarely studied. The goal was to identify interventricular differences in response to chronic VO.

Rats underwent aorto-caval fistula (ACF)/sham operation to induce VO. After 24 weeks, RV and left ventricular (LV) functions, gene expression and proteomics were studied. ACF led to biventricular dilatation, systolic dysfunction and hypertrophy affecting relatively more RV. Increased RV afterload contributed to larger RV stroke work increment compared to LV. Both ACF ventricles displayed upregulation of genes of myocardial stress and metabolism. Most proteins reacted to VO in a similar direction in both ventricles, yet the expression changes were more pronounced in RV. The most upregulated were extracellular matrix (POSTN, NRAP, TGM2, CKAP4), cell adhesion (NCAM, NRAP, XIRP2) and cytoskeletal proteins (FHL1, CSRP3) and enzymes of carbohydrate (PKM) or norepinephrine (MAOA) metabolism. Downregulated were MYH6 and FAO enzymes.

Therefore, when exposed to identical VO, both ventricles display similar upregulation of stress and metabolic markers. RV reacts to ACF relatively more than LV due to concomitant pulmonary hypertension. No evidence supports RV chamber-specific regulation of protein expression in response to VO.

Introduction

Due to current scope of heart failure (HF) epidemics, exploration of new approaches to prevent or stabilize HF is a priority for research. One of important milestones of HF progression is the onset of right ventricular failure due to transition of initially left ventricular disease into biventricular HF with dismal prognosis¹. Until recently, right ventricle (RV) received little attention and the mechanisms responsible for RV dysfunction are poorly understood^{2,3}. RV differs in many aspects from the LV, having different embryonic origin, geometry, wall thickness and operating pressures²⁻⁶. Whether these differences translate into a "RV-specific" response to increased hemodynamic stress is unknown. Such interventricular differences may theoretically represent a target for chamber-specific therapies.

RV dysfunction can develop due to pressure overload resulting from pulmonary hypertension and this scenario is often investigated^{7,3}. However, the response of RV to chronic volume overload (VO), a common contributing factor to HF, is studied much less⁸. The most frequent cause of VO of RV is severe tricuspid regurgitation that accompanies all forms of advanced HF⁹. Chronic VO of RV also occurs in patients with congenital heart disease¹⁰ or after implantation of left-ventricular assist device^{11,12}. Therefore, chronic VO of RV is common, yet understudied condition.

Few studies examined molecular mechanisms of volume-induced RV dysfunction^{8,10,13-17}. It is unclear whether RV response fundamentally differ from LV response to excessive VO. Function of ventricles exposed to VO is influenced by altered loading and geometry, so only load-independent assessment by simultaneous invasive pressure-volume analysis can provide insight into chamber-specific responses to VO. Advantageous model to study interventricular differences in stress response is chronic infrarenal aorto-caval fistula (ACF), a condition that imposes identical VO both on the left and the right heart, leading to biventricular cardiac hypertrophy, dilatation, dysfunction and symptomatic heart failure^{18 19}.

The goal of this study was to characterize the functional and molecular response of RV and LV to chronic VO and to identify hemodynamic factors that drive VO chamber remodeling using pressure-volume analysis, echocardiography, quantitative proteomics, and gene expression of selected genes previously implicated in development of RV failure¹⁴.

Results

Cardiac structure and function in response to VO

After 24 weeks of VO by ACF, we observed massive biventricular hypertrophy, relatively more pronounced on the right side (RV:+150%, LV:+70%, both $p < 0.0001$), increased atrial weight and increased lung weight due to congestion (Table 1). 70% of ACF animals showed clinical HF signs. ACF rats had similar tibial length as controls but were heavier due to presence of congestion.

Table 1
Baseline characteristics and echocardiography.

	Control	ACF	P (t-test)	fold-change ACF vs control
Body weight (BW), g	550 ± 50	610 ± 70	0.0035	1.1
Tibial length, mm	43 ± 1	44 ± 1	0.3668	1.0
Heart weight/BW, g.kg ⁻¹	3.0 ± 0.2	5.9 ± 0.8	< 0.0001	2.0
LV weight/BW, g.kg ⁻¹	2.0 ± 0.2	3.4 ± 0.5	< 0.0001	1.7
RV weight/BW, g.kg ⁻¹	0.53 ± 0.05	1.3 ± 0.2	< 0.0001	2.5
Atrial weight/BW, g.kg ⁻¹	0.33 ± 0.06	1.0 ± 0.2	< 0.0001	3.0
Lung weight/BW, g.kg ⁻¹	3.5 ± 0.4	5 ± 1	< 0.0001	1.4
Heart failure score (0–7)	0.03 ± 0.11	1.6 ± 1.5	< 0.0001	53
Echocardiography: Left ventricle (LV)				
LV end-diastolic dimension, mm	6.7 ± 0.6	12 ± 1	< 0.0001	1.8
LV posterior wall thickness, mm	2.6 ± 0.3	2.2 ± 0.2	< 0.0001	0.8
Relative wall thickness	0.8 ± 0.1	0.33 ± 0.05	< 0.0001	0.4
LV fractional shortening, %	58 ± 5	38 ± 6	< 0.0001	0.7
Heart rate, min ⁻¹	460 ± 30	370 ± 40	< 0.0001	0.8
Stroke volume, ml	0.29 ± 0.08	1.5 ± 0.3	< 0.0001	5.2
Cardiac output, ml.min ⁻¹	130 ± 30	500 ± 100	< 0.0001	3.8
Mitral regurgitation grade (1–4)	0.3 ± 0.5	1.3 ± 0.9	0.0004	4.3
Echocardiography: Right ventricle (RV)				
RVD1, mm	3.6 ± 0.3	7 ± 1	< 0.0001	1.9
RVD2, mm	3.5 ± 0.3	7 ± 1	< 0.0001	2.0
RVD3, mm	9.7 ± 0.7	14 ± 1	< 0.0001	1.4
RV diastolic area, mm ²	32 ± 2	90 ± 20	< 0.0001	2.8
RV FAC, %	49 ± 4	40 ± 10	0.0037	0.8
TAPSE, mm	3.1 ± 0.2	3.9 ± 0.7	< 0.0001	1.3
RV global strain, %	-9 ± 2	-13 ± 3	0.0005	1.4
RV global strain rate, s ⁻¹	1.4 ± 0.3	2.0 ± 0.4	< 0.0001	1.4
Tricuspid regurgitation grade (1–4)	0.4 ± 0.5	1.3 ± 0.8	0.0012	3.3
Values are expressed as mean ± SD.				

Echocardiography (Table 1, Fig. 1) confirmed LV chamber dilatation, wall thinning, eccentric remodeling, relative wall thinning and depressed global LV systolic function (LV fractional shortening: by -30%) in ACF animals. Due to the systemic shunt, cardiac output was increased in ACF. Right ventricle showed enlargement and reduced global systolic function (RV FAC: by -20%). Regional echocardiographic RV functional parameters (tricuspid annular plane systolic excursion-TAPSE, RV systolic strain) were influenced by marked ventricular remodeling/dilatation and overestimated RV systolic function.

Invasive hemodynamics and pressure-volume analysis (Table 2, Fig. 1) showed reduced systemic mean and diastolic blood pressure in ACF. End-diastolic filling pressures were increased in both ventricles, but more in the left ventricle. End-diastolic (and end-systolic) volumes were similarly increased in both ventricles. Maximal LV pressure and LV dP/dt_{max} were reduced, but maximal RV pressure and RV dP/dt_{max} were increased in ACF compared to controls. The difference between maximal RV pressure and LV end-diastolic pressure that reflects transpulmonary pressure gradient (and precapillary component of pulmonary hypertension), was increased in ACF by 25% compared to controls. Ventricular stroke work was markedly increased in both ventricles, but the increase was relatively larger in the right ventricle (RV: 6.4-fold and LV: 3.5-fold, respectively). Load-independent measure of chamber contractility - preload-recrutable stroke work (PRSW), was indeed significantly reduced both in ACF RV (by -30%, p = 0.0154) and LV (by -60%, p = 0.0021), confirming depressed systolic chamber function. LV diastolic function was impaired (relaxation constant tau increased by 50%, p < 0.0001; relaxation rate dP/dt_{min} decreased 2-fold, p < 0.0001) but RV diastolic function was not influenced by ACF.

Table 2
Hemodynamic data from pressure-volume analysis.

	Control	ACF	P (t-test)	fold-change ACF vs control
Systemic circulation				
SBP, mmHg	140 ± 30	130 ± 20	0.1164	0.9
DBP, mmHg	110 ± 30	80 ± 10	< 0.0001	0.7
MBP, mmHg	130 ± 30	110 ± 20	0.0024	0.8
PP, mmHg	29 ± 6	47 ± 8	< 0.0001	1.6
SVR, mmHg.min.ml ⁻¹	1 ± 0.3	0.21 ± 0.05	< 0.0001	0.2
Left Ventricle (LV)				
LV EDP, mmHg	6 ± 2	12 ± 4	< 0.0001	2.0
LV EDV, ml	0.31 ± 0.09	2.0 ± 0.5	< 0.0001	6.5
LV mass/EDV, g.ml ⁻¹	3.8 ± 0.9	1.1 ± 0.2	< 0.0001	0.3
LV ESV, ml	0.02 ± 0.01	0.5 ± 0.3	< 0.0001	25
LV max pressure, mmHg	150 ± 30	120 ± 20	< 0.0001	0.8
LV max wall stress, mmHg.ml.g ⁻¹	40 ± 10	120 ± 30	< 0.0001	3.0
Stroke work, mmHg.ml	20 ± 6	70 ± 20	< 0.0001	3.5
dP/dt _{max} , mmHg.s ⁻¹	10,000 ± 4,000	9,000 ± 3,000	0.1504	0.9
PRSW, mmHg	70 ± 40	30 ± 20	0.0021	0.4
dP/dt _{min} , mmHg.s ⁻¹	-11,000 ± 3,000	-5,000 ± 2,000	< 0.0001	0.5
Tau, ms	11 ± 2	17 ± 4	< 0.0001	1.5
Right ventricle (RV)				
RV EDP, mmHg	4 ± 1	6 ± 2	0.0028	1.5
RV EDV, ml	0.12 ± 0.01	0.7 ± 0.3	< 0.0001	5.8
RV mass/EDV, g.ml ⁻¹	2.4 ± 0.3	1.2 ± 0.3	< 0.0001	0.5
RV ESV, ml	0.038 ± 0.005	0.3 ± 0.2	< 0.0001	7.9
RV max pressure, mmHg	34 ± 5	46 ± 6	< 0.0001	1.4
RV max pressure - LVEDP gradient, mmHg	28 ± 6	35 ± 5	0.0023	1.3
RV max wall stress, mmHg.ml.g ⁻¹	15 ± 3	36 ± 9	< 0.0001	2.4
Stroke work, mmHg.ml	1.1 ± 0.1	7 ± 3	< 0.0001	6.4
dP/dt _{max} , mmHg.s ⁻¹	2,200 ± 800	2,900 ± 800	0.0265	1.3
PRSW, mmHg	30 ± 10	20 ± 10	0.0154	0.7
dP/dt _{min} , mmHg.s ⁻¹	-1,600 ± 300	-1,600 ± 400	0.9405	1.0
Tau, ms	20 ± 10	20 ± 10	0.9954	1.0
Values are expressed as mean ± SD.				

ACF had profound effect on duration of action potential (APD₉₀) that was similarly prolonged in both VO-exposed ventricles compared to controls (Fig. 2A, B). Trabecular contraction force had a trend towards RV-LV difference, without significant impact of ACF.

Expression of target genes in response to VO

Gene mRNA expression (qPCR) of selected genes (for list, see methods supplement) showed that ACF led to upregulation of myocardial stress genes (Fig. 3A): natriuretic peptide A (*Nppa*, more upregulated in LV than in RV) and increased myosin heavy chain isotype ratios (*Myh7/6*), mostly due to downregulated

Myh6 gene. Monoamine oxidase-A (*Maoa*) and transglutaminase-2 (*Tgm2*), genes previously associated with ACF²⁰, were similarly upregulated in RV and LV, apelin⁷ (*Apln*) was similarly downregulated in both ACF ventricles, with no effect of VO on apelin receptor (*Ap1nr*) (Figure S1).

Metabolic genes showed a pattern consistent with HF-induced reprogramming (Fig. 3B). Increased ratio of gene expression changes of Hexokinase 1 (*Hk1*) to Medium chain Acyl CoA dehydrogenase (*Acadm*) reflected enhanced glycolysis over the fatty acid oxidation in both ventricles. Increased ratio of glucose transporters *Glut1/Glut4* was consistent with increased non-insulin dependent glucose uptake in ACF ventricles, more pronounced in RV. In both ventricles, VO had no effect on genes related to tissue hypoxia and angiogenesis (*Vegf*, *Hif-1a*), only Angiopoetin 2/Angiopoetin 1 ratio was significantly increased in both ACF ventricles, more in the LV. Expression of genes of cGMP-dependent signaling pathway (natriuretic peptide receptor 1 and 2: *Npr1,2*, soluble guanylate cyclase: *Gucy1a3*, cGMP-dependent protein kinase: *Pkg*, phosphodiesterase 5: *Pde5a*, Phosphodiesterase 9: *Pde9a*), was not consistently affected by VO (Figure S1). Myocardial cGMP concentration was increased in ACF RV and LV (Figure S2), likely due to elevated levels of natriuretic peptides.

We correlated individual hemodynamic parameters with target gene expression changes in order to identify chamber-specific differences in response to VO (Fig. 2C, Table S1). The variable with strongest correlation to myocardial stress response genes (*Myh7/6 ratio*) and metabolic genes (*Glut1/4 ratio*) in both ventricles was end-diastolic volume and ventricular mass. For the same level of end-diastolic volume or mass increase, the gene expression in the RV was more pronounced (i.e. steeper regression slope) than in the LV. Such pattern, albeit weaker, was observed with other target genes. Directionality of gene expression-hemodynamics relations in RV corresponded to LV, with an important exemption of peak ventricular pressure (Fig. 2C). In the RV, higher maximal pressure linked with more pronounced gene expression, while in the LV, lower maximal pressure was associated with more remodeling. This indicates that ACF-induced changes in the right ventricle combine VO with simultaneous pressure overload, and lead to more pronounced gene expression changes, while the left ventricle in fact “pressure-unloaded” due to presence ACF combined with lower systemic pressures.

Ventricular proteome response to VO

Triplicate iTRAQ-based LC-MS/MS proteomic analysis of pooled samples of RVs and LVs of ACF and control animals identified over 3000 cardiac proteins. 1487 proteins were detected in all three replicates and provided quantitative expression data with adjusted p-value calculations. Only the proteins identified with at least 2 unique peptides (1372 proteins in total) were further considered (full list of identified proteins is provided as a supplementary dataset). 19 proteins were differentially expressed in both ACF ventricles (≥ 2 -fold change up or down with adjusted p-val < 0.05 vs. controls), 25 additional proteins met the same differential expression criteria only in the RV (all also trending in LV) and 3 proteins were differentially expressed in the LV only (also trending in RV) (Table 3, Fig. 4). The differentially expressed proteins due to ACF were thus highly concordant between RV and LV without evidence of any protein expression changes specific for either ventricle. Yet, the magnitude of the ACF-induced expression changes was more pronounced in the RV (approximate ratio across all quantified proteins 1:0.67, Fig. 4) than in the LV. The individual list of the most differentially regulated proteins (> 2-fold change up or down compared to controls) is presented in Table 3 and is discussed below. Expression changes of selected proteins were confirmed by western blotting using specific antibodies (Fig. 5).

Table 3
Differentially regulated proteins in RV vs LV due to volume overload.

Proteins differentially expressed in both ventricles (2-fold, adj. P-value<0.05)								RV (ACF/CTRL)		LV (ACF/CTRL)	
Gene	Description	Function	Rel*	Accession	C[%]	PSM	UP	Abundance Ratio: (115)/(114)	Adj. P-Value: (115)/(114)	Abundance Ratio: (117)/(116)	A P (1)
Postn	Periostin	ECM, myofibroblast activation, TGFbeta1 pathway	2	D3ZAF5	35	60	21	7.54	<0.001	3.43	<
Maoa	Amine oxidase [flavin-containing] A	degradation of catecholamines, ROS production	2	P21396	41	253	19	5.50	<0.001	3.38	<
Xirp2	Xin actin-binding repeat-containing protein 2	intercalated disc-associated protein, myofibril assembly	3	F1LMC2	29	166	72	4.87	<0.001	2.79	<
Ncam1	Neural cell adhesion molecule 1	intercalated disc protein, cell-cell adhesion	2	F1LNY3	22	32	14	4.56	0.003	4.31	0
Tgm2	Tissue-type transglutaminase	ECM cross-linking	2	Q9WVJ6	35	107	21	3.55	<0.001	2.41	<
Ighm	Immunoglobulin heavy constant mu	immunoglobulin component	0	A0A0G2K477	18	41	3	3.41	0.001	3.77	0
Nrap	Nebulin-related-anchoring protein	intercalated disk, actin-associated protein, myofibril assembly	2	D4A4K6	13	27	17	3.30	0.009	2.38	0
Kng1/2	Kininogen 1	bradykinin, coagulation	1	Q5PQU1	23	49	5	2.82	<0.001	2.91	<
Ckap4	Cytoskeleton-associated protein 4	ECM, myofibroblast activation	2	D3ZH41	56	28	12	2.60	0.001	2.43	0
Anxa5	Annexin A5	Ca2 + and phospholipid binding; apoptosis, sarcomere repair	2	P14668	69	215	19	2.53	<0.001	2.10	<
Prxl2a	Peroxiredoxin-like 2A	ROS defense protein	1	Q6AXX6	10	6	2	2.49	0.032	3.16	0
Fbn1	Fibrillin 1	ECM, microfibrils	2	G3V9M6	1	8	4	2.47	0.007	2.08	0
Hspb7	Heat shock 27kD protein family, member 7	sarcomere proteostasis, actin filament assembly	3	B5DFG4	46	22	6	2.20	0.013	2.00	0
Fhl1	Four and a half LIM domains 1	sarcomere stiffness regulation, titin binding	3	Q6P792	13	36	4	2.09	0.001	2.17	0
Coq10a	Coenzyme Q-binding protein COQ10 homolog A	mitochondrial; postnatal cardiomyocyte growth	1	A0A0G2JYY6	19	14	4	0.47	0.000	0.50	<
Decr1	2,4-dienoyl-CoA reductase	mitochondrial; beta oxidation of unsaturated FA	1	Q64591	31	37	9	0.27	<0.001	0.44	<
Pi4ka	Phosphatidylinositol 4-kinase alpha	first step of PI 4,5 biphosphate synthesis	0	O08662	1	4	2	0.26	0.001	0.31	0
Tmod4	Tropomodulin 4	thin filament capping	1	D3ZSG3	19	18	4	0.25	<0.001	0.49	0

Rel* - relevance to known association with myocardium or hearth failure (HF): 0: no reports, 1: known to be in the heart, 2: associates with HF phenotype, potentially modifies HF, 3: causally linked to HF, mutations are causal to HF/cardiomyopathy. C [%] – percentual coverage; UP – number of unique peptides; PSM – number of post translational modification.

Proteins differentially expressed in both ventricles (2-fold, adj. P-value<0.05)								RV (ACF/CTRL)		LV (ACF/CTRL)	
Myh6	Myosin-6	sarcomere, thick filament constituent	3	G3V885	67	5653	46	0.24	<0.001	0.28	<
Proteins differentially expressed in RV only (2-fold, adj. P-value<0.05)								RV (ACF/CTRL)		LV (ACF/CTRL)	
Synm	Synemin	cytoskeletal; intermediate filament component, signaling	3	A0A096MK54	26	33	20	2.54	0.001	1.71	0
Mvp	Major vault protein	ribonucleoprotein, nuclear membrane transport	0	Q62667	45	100	26	2.38	<0.001	1.93	<
Hspb1	Heat shock 27kDa protein 1	chaperone, mechanical stress response	2	G3V913	88	111	13	2.16	<0.001	1.69	<
Map1a	Microtubule-associated protein 1 A	cytoskeletal; microtubules, autophagy regulation	1	G3V7U2	15	56	28	2.16	<0.001	1.74	<
Uap1	UDP-N-acetylglucosamine pyrophosphorylase 1	GlcNAc glycosylation	0	D3ZF39	15	14	6	2.15	0.028	2.27	N
Pkm	Pyruvate kinase	glycolysis regulation	2	P11980	53	209	2	2.11	0.002	1.67	0
Xirp1	Xin actin-binding repeat containing 1	intercalated disc associated protein, myofibril assembly	3	D4ABA9	24	39	18	2.10	0.003	1.79	0
Csrp3	Cysteine and glycine rich protein 3	gene for cardiac LIM protein; myogenesis, stress-sensing	3	P50463	27	51	5	2.07	0.004	1.62	0
Nt5c2	5'-nucleotidase, cytosolic II	purine metabolism, DNA synthesis	1	D3ZMY7	10	17	4	2.07	0.003	1.50	0
Calu	Calumenin	Ca binding protein in ER/SR, Ca cycling, ER stress response	1	G3V6S3	57	47	12	2.07	<0.001	1.68	<
Ddah1	N(G),N(G)-dimethylarginine dimethylaminohydrolase 1	degradation of asymmetric dimethylarginine; NO signaling	2	O08557	34	41	8	2.06	<0.001	1.60	<
Vnn1	Vanin 1	pantothenate (vitamin B5) metabolism	0	Q4KLZ0	23	30	7	2.05	0.004	1.79	0
Ckb	Creatine kinase B-type	PCr/ATP metabolism, fetal isoform	2	P07335	57	209	14	2.01	<0.001	1.52	<
Myh10	Myosin, heavy polypeptide 10	non-muscle myosin; morphogenesis, cytokinesis	1	G3V9Y1	10	41	4	2.00	0.009	1.95	0
Cbr4	Carbonyl reductase family member 4	xenobiotic metabolism	1	Q7TS56	33	8	5	0.50	0.013	0.77	N
Ckmt2	Creatine kinase S-type, mitochondrial	PCr/ATP metabolism, sarcomeric form	2	P09605	41	609	14	0.49	<0.001	0.51	<
Rmdn1	Regulator of microtubule dynamics protein 1	microtubules, RNA splicing	0	Q4G069	33	47	9	0.47	<0.001	0.67	<
Col1a2	Collagen alpha-2(I) chain	ECM, fibrosis	1	F1LS40	2	5	3	0.47	0.029	0.65	N

Rel* - relevance to known association with myocardium or hearth failure (HF): 0: no reports, 1: known to be in the heart, 2: associates with HF phenotype, pot modifies HF, 3: causally linked to HF, mutations are causal to HF/cardiomyopathy. C [%] – percentual coverage; UP – number of unique peptides; PSM – num post translational modification.

Proteins differentially expressed in both ventricles (2-fold, adj. P-value < 0.05)								RV (ACF/CTRL)		LV (ACF/CTRL)	
Gstz1	Maleylacetoacetate isomerase	xenobiotic and glutathione metabolism	0	P57113	53	41	8	0.47	<0.001	0.85	N
Acsf2	Medium-chain acyl-CoA ligase ACSF2	fatty acid beta oxidation	0	Q499N5	42	165	18	0.47	<0.001	0.62	0
Coq8a	Atypical kinase COQ8A, mitochondrial	coenzyme Q10 biosynthesis	0	Q5BJQ0	39	103	16	0.46	0.002	0.53	0
MacroD1	ADP-ribose glycohydrolase MACROD1	RNA processing	1	Q8K4G6	26	26	6	0.45	<0.001	0.55	<
Hadhb	Trifunctional enzyme subunit beta	fatty acid beta oxidation	3	Q60587	54	226	20	0.44	<0.001	0.56	<
Hadha	Trifunctional enzyme subunit alpha	fatty acid beta oxidation	3	Q64428	49	562	31	0.44	<0.001	0.53	<
Adssl1	Adenylosuccinate synthetase isozyme 1	purine metabolism, AMP synthesis	1	M0R629	47	76	15	0.37	<0.001	0.57	<
Proteins differentially expressed in LV only (2-fold, adj. P-value < 0.05)								RV (ACF/CTRL)		LV (ACF/CTRL)	
Aldh1a1	Retinal dehydrogenase 1	retinoic acid metabolism	0	P51647	41	54	15	1.72	<0.001	2.08	<
C9	Complement component C9	innate immunity, membrane attack complex	2	Q62930	26	29	13	1.82	<0.001	2.11	<
Slc4a1	Band 3 anion transport protein	membrane transport	1	P23562	19	32	14	1.66	<0.001	3.69	<
Rel* - relevance to known association with myocardium or hearth failure (HF): 0: no reports, 1: known to be in the heart, 2: associates with HF phenotype, pote modifies HF, 3: causally linked to HF, mutations are causal to HF/cardiomyopathy. C [%] – percentual coverage; UP – number of unique peptides; PSM – num post translational modification.											

Discussion

The study describes biventricular changes in myocardial function and protein composition induced by chronic VO due to ACF. In response to ACF, both ventricles displayed eccentric hypertrophy, reduced contractility, prolonged duration of action potential, upregulation of genes associated with myocardial stress (*Nppa*, *Myh7/6 ratio*) and expression changes in substrate metabolic genes consistent with enhanced glycolysis and reduced fatty acid oxidation. By proteomic analysis, we identified several novel cardiac proteins differentially regulated by ACF with qualitatively concordant changes in both ventricles. The principal finding is that in response to identical surplus volume load, the pattern of proteome alterations is almost identical between ventricles, but the magnitude of changes is relatively more pronounced in the RV than in the LV. More pronounced changes on the right side can be explained by incremental RV pressure loading due to ACF-induced pulmonary vascular disease that combines with VO, while LV is exposed to lower systolic pressure due to a shunt in systemic circulation. Therefore, quantitative differences in protein expression between ventricles are explainable by hemodynamics, rather than by an existence of a “chamber-specific” regulation¹⁰. Study suggests that the primary approach how to preserve RV function and to prevent adverse RV remodeling in HF is to lower excessive hemodynamic loading.

VO-induced changes in biventricular hemodynamics, structure and function

Echocardiography showed eccentric remodeling, relative wall thinning, increased wall stress and depressed volumetric indices of function of both ventricles exposed to ACF. Indices of regional RV function (TAPSE, RV strain and strain rate) were paradoxically increased in ACF, likely due to confounding influence of chamber geometry, grossly changed by ACF. Therefore, TAPSE or strain deformation analysis overestimate RV contractility in volume overloaded ventricles. Limited utility of regional RV function indexes is also supported by low correlation of TAPSE, RV global strain and strain rate with gene expression of markers of myocardial remodeling (Table S1), in contrast to volumetric parameters.

Hemodynamic results are consistent with previous reports, although no study utilized pressure-volume analysis of both ventricles simultaneously in this model. While LV dP/dt_{max} showed a trend toward reduction in ACF compared to control^{19,21}, RV dP/dt_{max} was increased in ACF^{13,19}, reflecting either afterload-dependence of this parameter or heterometric (Frank-Starling) adaptation to increased load. Load-independent measure of chamber contractility - preload-recrutable stroke work (PRSW) was reduced in both ventricles, confirming indeed depressed systolic function¹⁵. Diastolic function (dP/dt_{min} and tau) was impaired in ACF LV, which might contribute to development of precapillary pulmonary hypertension component²².

Despite both ventricles handle the same increase in cardiac output in ACF, the increase in myocardial mass was relatively larger in the RV compared to LV (2.5 vs 1.7-fold, corresponding to LV/RV ratio of 0.7). Larger impact of ACF on RV compared to LV was noticed previously^{19,16,23}. The explanation could be in a different stress response compensation, or due to difference in regulation of cardiac growth between ventricles²⁴, or it can be explained hemodynamically. Our data support the latter mechanism. Pressure-volume data showed that ACF RV has to bear relatively higher increment of hemodynamic burden than LV. RV

stroke work is increased 6.4-fold while LV stroke work is increased 3.5-fold in ACF compared to normal. Larger loading of the RV can be explained by pulmonary hypertension that adds to VO of the right heart, likely due to latent pulmonary vascular disease²⁵ that is reflected by increased transpulmonary pressure gradient (RV peak pressure-LVEDP). Pulmonary vascular disease in ACF develops due to chronic elevation of pulmonary venous pressure²² and due to excessive pulmonary blood flow^{16,23,25}.

Isolated ventricular trabeculae showed lower attained contraction of RV compared to LV, but no impact of ACF on developed force or force-frequency relationship. Some^{21,26} but not all^{27,28} previous studies demonstrated reduced contractility of isolated cardiomyocytes²¹ or isolated papillary muscle preparations^{26,28} from rats with VO due to ACF. Further and more detailed analyses of RV and LV myofilament sensitivity are mandated. Both RV and LV from ACF group showed profound electrophysiological remodeling with almost doubling of action potential duration (APD) compared to controls. Prolongation of APD may be a compensatory mechanism how to maintain contraction strength in VO. APD prolongation is pro-arrhythmic and together with other mechanisms can contribute to increased risk of arrhythmic sudden death in volume-overloaded hearts²⁹.

VO-induced changes in biventricular mRNA gene expression

VO led to upregulation of gene for natriuretic peptide A (*Nppa*) in both ventricles^{8,13,30}. ACF-induced upregulation of ANP mRNA was massive and it was more pronounced in LV than in RV. In most HF animal models, including ACF³¹, as well as in humans with cardiac overload, the progression of cardiac hypertrophy into HF is associated with reduced expression of *Myh6* gene, coding α -myosin heavy chain, either absolutely or in relation to *Myh7*, gene of β -myosin heavy chain^{13,31,32}. Change of *Nppa* gene expression and *Myh7/6* ratio are therefore the most consistent molecular markers of HF and were upregulated in both VO-exposed ventricles. At a given surplus of mass, expression of *Nppa* or *Myh7/6* were more pronounced in RV than in LV (Fig. 2C). Correlation analysis (Table S1) also showed that changes of *Myh7/6* and *Nppa* expression changes are linked with similar hemodynamic variables, and are likely co-regulated, in contrast to metabolic genes.

Volume overload led to change in genes of myocardial substrate metabolism and bioenergetics, such as increased *Glut1/4* ratio, indicative of enhanced insulin-independent glucose uptake, and increased *Hk1/Mcad* ratio, indicative of enhanced glycolysis with reduced transcription of genes of fatty acid β -oxidation (*Mcad*). These changes were demonstrated in both ventricles. Similar pattern of metabolic gene transcription program was observed previously in pressure-overloaded ventricles, including RV³³. In summary, metabolic response to stress resembles a reactivation of fetal gene expression program and is uniform in terms of chamber (RV vs LV) or overload etiology³³.

We did not find altered expression of genes coding *Vegfa* and *Hif1a* in failing ventricles, but we observed increased ratio of *Angpt2/Angpt1* mRNA (coding antiangiogenic angiopoietin-1 and angiopoietin2), mostly in ACF LV, indicative of altered angiogenic signaling, similar to the response to myocardial infarction³⁴. There were no consistent differences in genes of cGMP-dependent signaling pathway, speaking against relevance of this pathway in response to VO. Yet myocardial cGMP concentration was increased in ACF ventricles, probably reflecting stimulation of NP receptor-associated (particulate) guanylate cyclase by elevated natriuretic peptides.

VO in both ventricles led to downregulation of apelin, a small peptide with cardioprotective, inotropic and angiogenic properties that has contra-regulatory effects to renin-angiotensin system and acts via apelin receptor (*Ap1nr*)³⁵. Downregulation of myocardial apelin was previously described in failing pressure-overloaded LV or RV^{7,35}, but this is the first study that links apelin to volume overload-induced remodeling.

VO-induced changes in biventricular proteome

VO-induced changes in protein abundance were mostly similar between RV and LV. All differentially expressed proteins were either concordantly altered (≥ 2 -fold change FC) in both ventricles, or significantly altered only in one ventricle with concordant and/or not significant change of expression in the second ventricle. The data thus provide no support for chamber-specific protein expression patterns in response to similar hemodynamic stress, as proposed previously on basis of interventricular differences in physiology and embryonic origin¹⁰. Yet, protein deregulation was more pronounced in the right ventricle than in left with ratio of 1:0.67, i.e. regression line was tilted from the line of equivalence towards RV (Fig. 4D). Interestingly, this ratio is numerically close to the ratio of ventricular mass increments (RV/LV mass ratio 1:0.7). Proteome data also agree with hemodynamic data, as ACF led to more pronounced change in stroke work and myocardial mass in RV than in LV.

Most proteins emerged as differentially and correspondingly regulated in both ACF ventricles, compared to sham-operated ventricles, some of them for the first time associated with response to VO. The analysis of these proteins helps to understand VO-induced myocardial remodeling shared by both ventricles and they will be discussed by functional groups.

Proteins related to extracellular matrix (ECM): The most upregulated protein in ACF ventricles was **periostin** (POSTN) - a non-structural component of ECM, marker of myofibroblasts, cells necessary for cardiac adaptive healing and fibrosis³⁶. Periostin assists in deposition of fibronectin-rich ECM and collagen crosslinking³⁷, cardiomyocyte dedifferentiation³⁸ and is extensively upregulated by TGF β 1, angiotensin II, infarction or hemodynamic overload, including VO^{39,40}. VO-driven upregulation is almost twice in RV than in LV. Another TGF β 1-regulated protein upregulated in ACF hearts is **cytoskeleton associated protein 4** (CKAP4), known to positively correlate with activated myofibroblast markers in both mouse and human cardiac tissue and to be negative modulator of fibroblast activation in injured heart⁴¹. We report again strong upregulation of **tissue-type transglutaminase 2** (TGM2) in both ACF ventricles²⁰, both on protein or mRNA level. TGM2 is responsible for crosslinking and stiffening of ECM and it was implicated in development of HF⁴². Another upregulated ECM protein is **Fibrillin-1**, a constituent of ECM microfibrils that is enhanced in ANGII-induced cardiac fibrosis⁴³.

Sarcomeric, cytoskeletal, and cell-cell interaction proteins: Second large group of upregulated proteins in ACF were cytoskeletal proteins, sarcomeric proteins and proteins responsible for cell-cell interaction/force transduction. We report here an upregulation of two Xin actin-binding repeat-containing proteins **XIRP1**

and **XIRP2**. These proteins with almost cardiac-specific expression are associated with intercalated disks and play a role in myofibril assembly and repair⁴⁴. XIRP2 modulates the effects of ANG-II on cardiac hypertrophy, fibrosis and myosin isotype switch⁴⁵, regulates voltage-gated K changes (KV1.5)⁴⁶, and was found to be upregulated in RV by experimental volume-overload⁴⁷. XIRPs may therefore represent potential markers of cardiac injury. Mutations of both XIRPs were associated with arrhythmic sudden cardiac death and prolonged action potential⁴⁶, a feature present also in VO-ACF hearts (Fig. 3B).

From other sarcomeric proteins, we found downregulated gene for **α -myosin heavy chain (MYH6)**, consistently with our targeted mRNA analysis and previous studies³². Across species and types of overload, the downregulation of MYH6 gene is one of the hallmarks of HF⁴⁸. ACF ventricles displayed also two-fold upregulation of non-muscle **myosin 10** and downregulation of **tropomodulin 4**. Upregulated cytoskeletal signaling protein **four and a-half LIM domains 1 (FHL-1)** which binds to and regulates titin stiffness was already linked to VO-induced cardiac LV remodeling in rats³⁰. Another sarcomeric stress-sensing element upregulated in ACF is cardiac **cysteine and glycine-rich protein 3 (CSRP3 aka MLP)**⁴⁹. Mutations in FHL1⁵⁰ and CSRP3 are known to cause cardiomyopathies. VO-ventricles showed an upregulation of **Annexin-5**, intracellular protein that participates in Ca²⁺ handling, apoptosis and sarcolemma repair and is upregulated in failing human myocardium⁵¹.

One of the most upregulated proteins in ACF ventricles was **neural cell adhesion molecule 1 (NCAM1, 4.5-fold)**, a plasma membrane protein relevant for cardiomyocyte cell-cell interactions. NCAM1 is, similarly to identified ECM proteins, regulated by TGF β ⁵² and overexpressed in cardiomyocytes of other HF models and failing human hearts, proportionally to severity of HF⁵³. Another VO-upregulated protein involved in cell-cell interactions is **nebulin-related anchoring protein (NRAP)**, an actin-associated protein localized in intercalated disc, implicated in sarcomere assembly and force transduction. NRAP overexpression in the mouse leads to right ventricular cardiomyopathy⁵⁴. Intermediate filament protein **synemin (SYNM)** that stabilizes intercalated disc and participates in protein kinase A signaling was also upregulated; its absence leads to severe cardiac abnormalities⁵⁵. ACF ventricles showed an upregulation of **microtubule-associated protein 1A (MAP1A)**, not previously associated with HF, and upregulation of **major vault protein** – a member of ribonucleoprotein complex relevant for nucleo-cytoplasmatic transport⁵⁶.

Metabolic genes, ROS and chaperones: Proteomic analysis confirmed upregulation of glycolytic enzymes and downregulation of FA oxidation seen in targeted PCR analysis. Specifically, ACF ventricles showed upregulation of **pyruvate kinase (PKM)**, the final enzyme of glycolysis. Upregulation of fetal isoform (PKM2) was previously observed in failing RV due to PH⁵⁷. In parallel, we observed downregulation of α and β subunits of **trifunctional enzyme** of β -oxidation of fatty acids (**HADHA, HADHB**), more pronounced in volume-overloaded RV than in LV, consistent with switch in myocardial metabolic preference typical to fetal or failing heart^{33,39}. Downregulation of mitochondrial 2,4-dienoyl-CoA reductase, an enzyme of β -oxidation of unsaturated fatty acids, was also observed in both VO ventricles. We observed an upregulation of B (fetal) **isoform of creatine kinase (CK-B)** that is typical for failing heart⁵⁸ and a downregulation of its mitochondrial sarcomeric isoform (**CKMT2**), suggesting abnormalities in creatine shuttle and energy transfer.

Both ACF ventricles, but more RV, display strong upregulation of monoaminoxidase-A (**MAOA**), an enzyme that is responsible for degradation of catecholamines²⁰. Upregulation of MAOA in ACF ventricles verifies our previous observation and is confirmed also on mRNA level (Fig. 3A) and by western blot (Fig. 5). MAOA might protect myocardium from untoward effects of increased norepinephrine spillover, but it is also a ROS-producing enzyme⁵⁹. If MAO-A upregulation is adaptive or maladaptive in failing myocardium is therefore not known.

Both ACF ventricles showed upregulation of heat shock proteins: **HSPB7** and HSPB1. HSPB7 is expressed almost exclusively in striated muscle and is critical for cardiac sarcomere assembly and proteostasis⁶⁰. Genome-wide association study found that variation in HSPB7 locus is associated with reduced LV ejection fraction⁶¹.

Failing ACF ventricles (more RV than LV) showed upregulated dimethylarginine dimethylhydrolase1 (**DDAH1**), an enzyme that degrades asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric synthase. DDAH1-deficient rats have more severe PH and RV failure if exposed to monocrotaline⁶². In contrast, end-stage HF patients without PH have upregulated myocardial DDAH suggesting a contraregulatory response to putative ADMA elevation and ensuing NO deficit⁶³.

The study has several limitations. To reduce variance, only male rats were studied. Cardiac tolerance to volume overload is worse in males than in females, i.e. changes were more pronounced⁶⁴. Hemodynamics was tested only in resting state, without provocation maneuvers that could discern more subtle changes in cardiac function. Preload changing maneuvers (vena cava balloon inflation) were not performed due to technical reasons, i.e. we cannot report arterial or ventricular elastance values. Proteomic analysis did not detect some proteins that are known to be differentially regulated in HF and were even detected at mRNA level, such as collagens, apelin or apelin receptor. Such discrepancy can be explained by very low expression, insufficient solubility or low molecular weight of the protein with insufficient number of peptides generated by trypsin.

In conclusion, the study showed that ACF led to changes of molecular markers of heart failure, increased cardiac stress and altered substrate metabolism in both ventricles. RV reacted to ACF relatively more than LV, likely due to larger incremental stroke work due to pulmonary hypertension. Proteomic analysis identified high interventricular concordance of ACF-induced changes, indicating that the RV vs LV differences are explainable hemodynamically, rather than by a presence of “RV-specific” regulatory pathways. Reduction of PA pressure and RV load is therefore the primary instrument how to preserve RV function and adverse remodeling.

Methods

(for details, see supplementary information)

Heart failure model

Eight-week male Sprague Dawley rats underwent needle ACF/sham operation as described previously^{18,65}. After 24 weeks, RV and LV function (echocardiography, biventricular pressure-volume analysis, action potential duration), target gene expression (qPCR) and proteomics (LC-MS/MS) were studied. The investigation conformed to the NIH Guide for the care and use of laboratory animals (NIH Publication No. 85 – 23, 1996), Animal protection laws of the Czech Republic (311/1997) and was approved by the Ethic Committee of IKEM.

Echocardiography and Hemodynamics

Echocardiography was performed under general anesthesia with 10 MHz transducer (Vivid System 7, GE, USA). RV fractional area change (FAC) was defined as difference of end-diastolic and end-systolic RV area, divided by end-diastolic area. RV volumes were calculated using monoplane ellipsoid approximation method⁶⁶. Subsequently, ventricular function was invasively assessed by 2F Pressure–Volume micromanometer-tip catheters (Millar Instruments, Houston, TX, USA) simultaneously introduced into the LV via the right carotid artery and into the RV via the internal jugular vein. Data were analysed by LABCHART PRO software (ADInstruments, Bella Vista, NSW, Australia).

Contractility and action potential duration measurements

The papillary muscles were dissected from both ventricles. Contraction force and membrane potential was measured as described elsewhere⁶⁷. Action potential duration (APD) was measured at 50% and 90% levels of repolarization (APD50, APD90).

Gene expression analysis

Samples were taken from RV and LV free wall and placed into RNA later. Total RNA was isolated and genomic DNA removed. RNA quantity and integrity were measured. The RNA was reverse transcribed and qPCR was done using RealTime ready Custom Panel 384–32 (Roche, p.n. 05 582 962 001). The analysis was performed on a LightCycler LC480 (Roche) according to manufacturer's protocol. Resulting data were analyzed by the ΔC_p method using the R/Bioconductor statistical environment^{68–70}.

Proteomic analysis

All chemicals were from Sigma-Aldrich, unless stated otherwise. Pooled pulverized myocardial samples were lysed, digested with trypsin using and labeled with four iTRAQ tags according to the manufacturer's instructions⁷¹. The samples were labeled as follows: tags as follows: 114: right ventricle/control, 115: right ventricle/ACF, 116: left ventricle/control, 117: left ventricle/ACF. To remove unbound tags and to pre-fractionate the peptides into four fractions SCX OPTI-TRAP™ Cartridge (Optimized Technologies, OR, USA) was used. Labeled peptide fractions were desalted and dried before LC-MS/MS analysis. 50 cm EASY-Spray column (EASY-Spray column, 50 cm x 75 μ m ID, PepMap C18, 2 μ m particles, 100 Å pore size) with EASY-Spray™ Source with PepMap100 Pre-column was used for on-line peptide fractionation. A linear gradient was applied for 240 minutes using Ultimate 3000 Nano LC (Dionex). Data were collected on Thermo Orbitrap Fusion™ in MS³ reporter ion quantification mode. The top 10 most intensive peaks from MS² fragmentation were simultaneously selected and fragmented in HCD, MS³ masses were acquired in the Orbitrap. In total, three independent iTRAQ analyses using the same pooled myocardial samples were performed. The raw data from all three analyses (each comprising of 4 SCX fractions) were merged and analyzed in Proteome Discoverer 2.2. Data were searched against Rat SwissProt and TrEMBL databases using Sequest HT. FDR 0.01 limit for peptides and proteins was set. Quantitative data were normalized on total peptide amount. Unique and razor peptides were used for quantification.

Western blot analysis

Pulverized pooled heart samples were lysed, denatured and separated by SDS-PAGE. Proteins were transferred to PVDF membranes, which were then blocked and probed first with primary and then with HRP-conjugated secondary antibodies. The signal was detected using ECL detection system.

Statistical analysis

Data were assembled and statistically analyzed using JMP 14 software package (SAS, USA). Groups were compared using Student's t test and Pearson's correlation coefficient was used for assessment of correlation between continuous variables. Results are expressed as means $\pm$ SD, if not stated otherwise. P-value less than 0.05 was considered significant.

Declarations

Data availability

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

Author contributions statement

V.M., J.P. and T.H. wrote the manuscript. V.M., J.P., L.C., J.B., M.S. and M.K. designed the experiments. T.H., P.S., M.B., M.Ch., M.M., D.J., J.S. and J.N. carried out the lab work and/or analyzed the data. All authors commented and approved the final version of the manuscript.

Acknowledgements

This work has been supported by The Czech Agency for Healthcare Research (grants AZV 17-28784A, NV19-02-00130, NU20-02-00052), Czech National Infrastructure for Biological data (ELIXIR CZ, MEYS Grant No. LM2018131JN) and Charles University (Progres Q39 and Q26, SVV 260521, and UNCE/MED/016).

Additional information

Conflict of interest: There is no conflict of interest of any author of this manuscript.

Correspondence: Correspondence and requests for materials should be addressed to V.M.

Supplementary Information: Expanded Materials & Methods section together with additional figures, tables and supplementary proteomic dataset are provided in the supplementary material.

References

1. Melenovsky, V. *et al.* Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. *J Am Coll Cardiol.* **62**, 1660–1670 <https://doi.org/10.1016/j.jacc.2013.06.046> (2013).
2. Voelkel, N. F. *et al.* Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. *Circulation.* **114**, 1883–1891 <https://doi.org/10.1161/CIRCULATIONAHA.106.632208> (2006).
3. Haddad, F., Hunt, S. A., Rosenthal, D. N. & Murphy, D. J. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. *Circulation.* **117**, 1436–1448 <https://doi.org/10.1161/CIRCULATIONAHA.107.653576> (2008).
4. Amsallem, M., Mercier, O., Kobayashi, Y., Moneghetti, K. & Haddad, F. Forgotten No More: A Focused Update on the Right Ventricle in Cardiovascular Disease. *JACC. Heart failure.* **6**, 891–903 <https://doi.org/10.1016/j.jchf.2018.05.022> (2018).
5. Haddad, F., Doyle, R., Murphy, D. J. & Hunt, S. A. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. *Circulation.* **117**, 1717–1731 <https://doi.org/10.1161/CIRCULATIONAHA.107.653584> (2008).
6. Sanz, J. *et al.* Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review. *J Am Coll Cardiol.* **73**, 1463–1482 <https://doi.org/10.1016/j.jacc.2018.12.076> (2019).
7. Drake, J. I. *et al.* Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. *Am J Respir Cell Mol Biol.* **45**, 1239–1247 <https://doi.org/10.1165/rcmb.2010-0412OC> (2011).
8. Bartelds, B. *et al.* Differential responses of the right ventricle to abnormal loading conditions in mice: pressure vs. volume load. *Eur J Heart Fail.* **13**, 1275–1282 <https://doi.org/10.1093/eurjhf/hfr134> (2011).
9. Wang, N. *et al.* Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. *European heart journal.* **40**, 476–484 <https://doi.org/10.1093/eurheartj/ehy641> (2019).
10. Reddy, S. & Bernstein, D. Molecular Mechanisms of Right Ventricular Failure. *Circulation.* **132**, 1734–1742 <https://doi.org/10.1161/CIRCULATIONAHA.114.012975> (2015).
11. Houston, B. A., Shah, K. B., Mehra, M. R. & Tedford, R. J. A new "twist" on right heart failure with left ventricular assist systems. *J Heart Lung Transplant.* **36**, 701–707 <https://doi.org/10.1016/j.healun.2017.03.014> (2017).
12. Lampert, B. C. & Teuteberg, J. J. Right ventricular failure after left ventricular assist devices. *J Heart Lung Transplant.* **34**, 1123–1130 <https://doi.org/10.1016/j.healun.2015.06.015> (2015).
13. Bossers, G. P. L. *et al.* Volume load-induced right ventricular dysfunction in animal models: insights in a translational gap in congenital heart disease. *Eur J Heart Fail.* **20**, 808–812 <https://doi.org/10.1002/ejhf.931> (2018).
14. Reddy, S. *et al.* Physiologic and molecular characterization of a murine model of right ventricular volume overload. *American journal of physiology. Heart and circulatory physiology.* **304**, H1314–1327 <https://doi.org/10.1152/ajpheart.00776.2012> (2013).
15. Borgdorff, M. A. *et al.* Distinct loading conditions reveal various patterns of right ventricular adaptation. *American journal of physiology. Heart and circulatory physiology.* **305**, H354–364 <https://doi.org/10.1152/ajpheart.00180.2013> (2013).
16. Modesti, P. A. *et al.* Different growth factor activation in the right and left ventricles in experimental volume overload. *Hypertension.* **43**, 101–108 <https://doi.org/10.1161/01.HYP.0000104720.76179.18> (2004).
17. Toischer, K. *et al.* Differential cardiac remodeling in preload versus afterload. *Circulation.* **122**, 993–1003 <https://doi.org/10.1161/CIRCULATIONAHA.110.943431> (2010).
18. Melenovsky, V. *et al.* The course of heart failure development and mortality in rats with volume overload due to aorto-caval fistula. *Kidney & blood pressure research.* **35**, 167–173 <https://doi.org/10.1159/000331562> (2012).
19. Liu, Z., Hilbelink, D. R. & Gerdes, A. M. Regional changes in hemodynamics and cardiac myocyte size in rats with aortocaval fistulas. 2. Long-term effects. *Circulation research.* **69**, 59–65 <https://doi.org/10.1161/01.res.69.1.59> (1991).
20. Petrak, J. *et al.* Proteomic and transcriptomic analysis of heart failure due to volume overload in a rat aorto-caval fistula model provides support for new potential therapeutic targets - monoamine oxidase A and transglutaminase 2. *Proteome Sci.* **9**, 69 <https://doi.org/10.1186/1477-5956-9-69> (2011).
21. Guggilam, A. *et al.* In vivo and in vitro cardiac responses to beta-adrenergic stimulation in volume-overload heart failure. *Journal of molecular and cellular cardiology.* **57**, 47–58 <https://doi.org/10.1016/j.yjmcc.2012.11.013> (2013).
22. Breitling, S., Ravindran, K., Goldenberg, N. M. & Kuebler, W. M. The pathophysiology of pulmonary hypertension in left heart disease. *Am J Physiol Lung Cell Mol Physiol.* **309**, L924–941 <https://doi.org/10.1152/ajplung.00146.2015> (2015).
23. Rungtatscher, A. *et al.* Chronic overcirculation-induced pulmonary arterial hypertension in aorto-caval shunt. *Microvasc Res.* **94**, 73–79 <https://doi.org/10.1016/j.mvr.2014.05.005> (2014).

24. Borgdorff, M. A. *et al.* Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. *European journal of heart failure*. **14**, 1067–1074 <https://doi.org/10.1093/eurjhf/hfs094> (2012).
25. Linardi, D. *et al.* Ventricular and pulmonary vascular remodeling induced by pulmonary overflow in a chronic model of pretricuspid shunt. *J Thorac Cardiovasc Surg*. **148**, 2609–2617 <https://doi.org/10.1016/j.jtcvs.2014.04.044> (2014).
26. Gealekman, O., Abassi, Z., Rubinstein, I., Winaver, J. & Binah, O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. *Circulation*. **105**, 236–243 <https://doi.org/10.1161/hc0202.102015> (2002).
27. Ryan, T. D. *et al.* Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload. *Journal of the American College of Cardiology*. **49**, 811–821 <https://doi.org/10.1016/j.jacc.2006.06.083> (2007).
28. Hisamatsu, Y. *et al.* Early changes in the functions of cardiac sarcoplasmic reticulum in volume-overloaded cardiac hypertrophy in rats. *J Mol Cell Cardiol*. **29**, 1097–1109 <https://doi.org/10.1006/jmcc.1996.0327> (1997).
29. Sedmera, D. *et al.* Changes in Myocardial Composition and Conduction Properties in Rat Heart Failure Model Induced by Chronic Volume Overload. *Frontiers in physiology*. **7**, 367 <https://doi.org/10.3389/fphys.2016.00367> (2016).
30. Hutchinson, K. R., Saripalli, C., Chung, C. S. & Granzier, H. Increased myocardial stiffness due to cardiac titin isoform switching in a mouse model of volume overload limits eccentric remodeling. *J Mol Cell Cardiol*. **79**, 104–114 <https://doi.org/10.1016/j.yjmcc.2014.10.020> (2015).
31. Freire, G., Ocampo, C., Ilbawi, N., Griffin, A. J. & Gupta, M. Overexpression of AP-1 reduces alpha myosin heavy chain expression and contributes to heart failure from chronic volume overload. *Journal of molecular and cellular cardiology*. **43**, 465–478 <https://doi.org/10.1016/j.yjmcc.2007.07.046> (2007).
32. Wilson, K. *et al.* Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure. *American journal of physiology. Heart and circulatory physiology*. **307**, H1605–1617 <https://doi.org/10.1152/ajpheart.00423.2014> (2014).
33. Koop, A. C. *et al.* Metabolic Remodeling in the Pressure-Loaded Right Ventricle: Shifts in Glucose and Fatty Acid Metabolism-A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. **8**, e012086 <https://doi.org/10.1161/JAHA.119.012086> (2019).
34. Sandhu, R. *et al.* Reciprocal regulation of angiotensin-1 and angiotensin-2 following myocardial infarction in the rat. *Cardiovascular research*. **64**, 115–124 <https://doi.org/10.1016/j.cardiores.2004.05.013> (2004).
35. Dalzell, J. R. *et al.* The Emerging Potential of the Apelin-APJ System in Heart Failure. *Journal of cardiac failure*. **21**, 489–498 <https://doi.org/10.1016/j.cardfail.2015.03.007> (2015).
36. Kanisicak, O. *et al.* Genetic lineage tracing defines myofibroblast origin and function in the injured heart. *Nat Commun*. **7**, 12260 <https://doi.org/10.1038/ncomms12260> (2016).
37. Landry, N. M., Cohen, S. & Dixon, I. M. C. Periostin in cardiovascular disease and development: a tale of two distinct roles. *Basic Res Cardiol*. **113**, 1 <https://doi.org/10.1007/s00395-017-0659-5> (2018).
38. Bruns, D. R. *et al.* The right ventricular fibroblast secretome drives cardiomyocyte dedifferentiation. *PLoS One*. **14**, e0220573 <https://doi.org/10.1371/journal.pone.0220573> (2019).
39. Melenovsky, V. *et al.* Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats. *Molecular and cellular biochemistry*. **354**, 83–96 <https://doi.org/10.1007/s11010-011-0808-3> (2011).
40. Chen, Y. W. *et al.* Dynamic molecular and histopathological changes in the extracellular matrix and inflammation in the transition to heart failure in isolated volume overload. *Am J Physiol Heart Circ Physiol*. **300**, H2251–2260 <https://doi.org/10.1152/ajpheart.01104.2010> (2011).
41. Gladka, M. M. *et al.* Single-Cell Sequencing of the Healthy and Diseased Heart Reveals Cytoskeleton-Associated Protein 4 as a New Modulator of Fibroblasts Activation. *Circulation*. **138**, 166–180 <https://doi.org/10.1161/CIRCULATIONAHA.117.030742> (2018).
42. Shinde, A. V. *et al.* Tissue transglutaminase induction in the pressure-overloaded myocardium regulates matrix remodelling. *Cardiovascular research*. **113**, 892–905 <https://doi.org/10.1093/cvr/cvx053> (2017).
43. Bouzeghrane, F., Reinhardt, D. P., Reudelhuber, T. L. & Thibault, G. Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis. *Am J Physiol Heart Circ Physiol*. **289**, H982–991 <https://doi.org/10.1152/ajpheart.00151.2005> (2005).
44. Leber, Y. *et al.* Filamin C is a highly dynamic protein associated with fast repair of myofibrillar microdamage. *Hum Mol Genet*. **25**, 2776–2788 <https://doi.org/10.1093/hmg/ddw135> (2016).
45. McCalmon, S. A. *et al.* Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2. *Circ Res*. **106**, 952–960 <https://doi.org/10.1161/CIRCRESAHA.109.209007> (2010).
46. Huang, L. *et al.* Critical Roles of Xirp Proteins in Cardiac Conduction and Their Rare Variants Identified in Sudden Unexplained Nocturnal Death Syndrome and Brugada Syndrome in Chinese Han Population. *J Am Heart Assoc*. **7**, <https://doi.org/10.1161/JAHA.117.006320> (2018).
47. Charron, S. *et al.* Identification of Region-Specific Myocardial Gene Expression Patterns in a Chronic Swine Model of Repaired Tetralogy of Fallot. *PLoS One*. **10**, e0134146 <https://doi.org/10.1371/journal.pone.0134146> (2015).
48. Lowes, B. D. *et al.* Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. *J Clin Invest*. **100**, 2315–2324 <https://doi.org/10.1172/JCI119770> (1997).
49. Buyandelger, B. *et al.* MLP (muscle LIM protein) as a stress sensor in the heart. *Pflügers Archiv: European journal of physiology*. **462**, 135–142 <https://doi.org/10.1007/s00424-011-0961-2> (2011).
50. Hartmannova, H. *et al.* Isolated X-linked hypertrophic cardiomyopathy caused by a novel mutation of the four-and-a-half LIM domain 1 gene. *Circulation. Cardiovascular genetics*. **6**, 543–551 <https://doi.org/10.1161/CIRCGENETICS.113.000245> (2013).

51. Camors, E., Monceau, V. & Charlemagne, D. Annexins and Ca²⁺ handling in the heart. *Cardiovasc Res.* **65**, 793–802 <https://doi.org/10.1016/j.cardiores.2004.11.010> (2005).
52. Ackermann, M. A. *et al.* TGF-beta1 affects cell-cell adhesion in the heart in an NCAM1-dependent mechanism. *J Mol Cell Cardiol.* **112**, 49–57 <https://doi.org/10.1016/j.yjmcc.2017.08.015> (2017).
53. Nagao, K. *et al.* Myocardial expression level of neural cell adhesion molecule correlates with reduced left ventricular function in human cardiomyopathy. *Circulation. Heart failure.* **7**, 351–358 <https://doi.org/10.1161/CIRCHEARTFAILURE.113.000939> (2014).
54. Lu, S. *et al.* Cardiac-specific NRAP overexpression causes right ventricular dysfunction in mice. *Experimental cell research.* **317**, 1226–1237 <https://doi.org/10.1016/j.yexcr.2011.01.020> (2011).
55. Garcia-Pelagio, K. P. *et al.* Absence of synemin in mice causes structural and functional abnormalities in heart. *Journal of molecular and cellular cardiology.* **114**, 354–363 <https://doi.org/10.1016/j.yjmcc.2017.12.005> (2018).
56. Shults, N. V., Das, D. & Suzuki, Y. J. Major vault protein in cardiac and smooth muscle. *Receptors & clinical investigation* **3**(2016).
57. Xiong, P. Y. *et al.* Biventricular Increases in Mitochondrial Fission Mediator (MiD51) and Proglycolytic Pyruvate Kinase (PKM2) Isoform in Experimental Group 2 Pulmonary Hypertension-Novels Mitochondrial Abnormalities. *Frontiers in cardiovascular medicine.* **5**, 195 <https://doi.org/10.3389/fcvm.2018.00195> (2018).
58. Shen, W. *et al.* The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. *Journal of molecular and cellular cardiology.* **39**, 537–544 <https://doi.org/10.1016/j.yjmcc.2005.05.003> (2005).
59. Kaludercic, N., Mialet-Perez, J., Paolocci, N., Parini, A. & Di Lisa, F. Monoamine oxidases as sources of oxidants in the heart. *J Mol Cell Cardiol.* **73**, 34–42 <https://doi.org/10.1016/j.yjmcc.2013.12.032> (2014).
60. Mercer, E. J., Lin, Y. F., Cohen-Gould, L. & Evans, T. Hsp7 is a cardioprotective chaperone facilitating sarcomeric proteostasis. *Dev Biol.* **435**, 41–55 <https://doi.org/10.1016/j.ydbio.2018.01.005> (2018).
61. Aung, N. *et al.* Genome-Wide Analysis of Left Ventricular Image-Derived Phenotypes Identifies Fourteen Loci Associated With Cardiac Morphogenesis and Heart Failure Development. *Circulation.* **140**, 1318–1330 <https://doi.org/10.1161/CIRCULATIONAHA.119.041161> (2019).
62. Wang, D. *et al.* Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats. *International journal of cardiology.* **295**, 14–20 <https://doi.org/10.1016/j.ijcard.2019.07.078> (2019).
63. Shao, Z. *et al.* Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. *Journal of the American College of Cardiology.* **59**, 1150–1158 <https://doi.org/10.1016/j.jacc.2011.12.022> (2012).
64. El Hajj, M. C., Ninh, V. K., Hajj, E., Bradley, E. C., Gardner, J. D. & J. M. & Estrogen receptor antagonism exacerbates cardiac structural and functional remodeling in female rats. *American journal of physiology. Heart and circulatory physiology.* **312**, H98–H105 <https://doi.org/10.1152/ajpheart.00348.2016> (2017).
65. Cervenka, L. *et al.* Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula. *Clinical and experimental pharmacology & physiology.* **42**, 795–807 <https://doi.org/10.1111/1440-1681.12419> (2015).
66. Lange, P. E. *et al.* Value of image enhancement and injection of contrast medium for right ventricular volume determination by two-dimensional echocardiography in congenital heart disease. *Am J Cardiol.* **55**, 152–157 [https://doi.org/10.1016/0002-9149\(85\)90318-2](https://doi.org/10.1016/0002-9149(85)90318-2) (1985).
67. Svirglerova, J. *et al.* Cardiac remodeling in rats with renal failure shows interventricular differences. *Exp Biol Med (Maywood).* **237**, 1056–1067 <https://doi.org/10.1258/ebm.2012.012045> (2012).
68. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-(Delta Delta C(T))} Method. *Methods.* **25**, 402–408 <https://doi.org/10.1006/meth.2001.1262> (2001).
69. Huber, W. *et al.* Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods.* **12**, 115–121 <https://doi.org/10.1038/nmeth.3252> (2015).
70. McCall, M. N., McMurray, H. R., Land, H. & Almudevar, A. On non-detects in qPCR data. *Bioinformatics.* **30**, 2310–2316 <https://doi.org/10.1093/bioinformatics/btu239> (2014).
71. Wisniewski, J. R., Zougman, A., Nagaraj, N. & Mann, M. Universal sample preparation method for proteome analysis. *Nat Methods.* **6**, 359–362 <https://doi.org/10.1038/nmeth.1322> (2009).

Figures

Figure 1

Volume overload-induced cardiac remodeling of right (RV) and left (LV) ventricle. a) Representative example of pressure-volume (PV) loops in HF and controls. b) Echocardiographic parasternal short axis view of LV in M-mode, c) 4-chamber view of RV in controls and ACF. d) Hemodynamic parameters and PV analysis results in ACF (N=26) and controls (N=16). Data are presented as means $\pm$ SD. * $p < 0.05$ vs controls.

Action potential and contraction force

Figure 2

Biventricular differences in contraction force, action potential duration and mRNA expression regulation in volume overload from aorto-caval fistula (ACF). a) Example of action potential recording from isolated papillary muscle. b left) Action potential duration at 90% repolarization (APD₉₀) in RV and LV papillary muscles in controls and in ACF rats. Measurements at stimulation frequencies of 0.5, 1, 2, 3.3 and 5 Hz. *, $p < 0.05$, RV control vs. RV ACF; #, $p < 0.05$, LV control vs. LV ACF (3-way ANOVA). b right) Maximal contraction force in RV and LV papillary muscles in control and ACF rats. c) Relation of hypertrophy determinants to gene mRNA expression patterns in RV and LV. Note discordant relations between gene expression and ventricular pressures; concordant but steeper relation of RV compared to LV.

Figure 3

Gene mRNA expression analysis of cardiac markers of stress and metabolism. Gene mRNA expression analysis of selected genes that reflect a) myocardial stress, b) substrate metabolism and bioenergetics. Data are presented as means $\pm$ SEM. Changes normalized to control RV. N=12 in each group. P value: ANOVA, and Tukey post-hoc tests.

Figure 4

iTRAQ proteomic analysis of biventricular response to volume overload due to ACF. a, b) Volcan plot of identified proteins in RV and LV. X axis represent $\log_2$ of fold change compared to controls, Y axis $-\log_{10}$ of p-value. c) Venn diagrams of differentially regulated proteins in ACF compared to controls (significant difference with threshold > 1.5 -fold). d) ACF-induced changes ($\log_2$ of fold-) in RV (X axis) vs LV (Y axis). Note departure of the regression line (with 95% CI, red) from identity line (dashed), towards RV. The proteins with relatively highest differential regulation in RV are labeled in red. For abbreviations, see text.

Figure 5

Confirmation of the differential expression of selected proteins using western blot analysis with specific antibodies. Pooled myocardial samples (40 µg) were loaded and separated in duplicates. GAPDH was used as a loading control. NCAM-1 (Neural cell adhesion molecule 1), TGM2 (Tissue-type transglutaminase), MAO-A (Monoamine oxidase type A).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryInformationHavlenovaetal.pdf](#)
- [SupplementaryProteomicDataset.xlsx](#)